Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human Flt3-Ligand Protein, 50µg  

Recombinant Human Flt3-Ligand Protein, 50µg

Human Flt-3 Ligand Protein, AA Thr 27 - Pro 185, expressed from human 293 cells (HEK293), His Tag

Synonym: Recombinant Protein, FLT3LG, FL, FLT3L, Flt3 ligand

 

More details

FLL-H5223-050

Availability: within 7 days

420,00 €

Background
FMS-like tyrosine kinase 3 ligand (Flt-3 Ligand) is also known as FL, Flt3L and FLT3LG, is an α-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages. FLT3LG is expressed as a noncovalentlylinked dimer by T cells and bone marrow and thymic fibroblasts. Each 36 kDa chain carries approximately 12 kDa of N- and O- linked carbohydrates. FLT3LG is structurally homologous to stem cell factor (SCF) and colony stimulating facor 1 (CSF-1). FLT3LG acts as a growth factor that increases the number of immune cells by activating the hematopoietic progenitors. It also induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3LG induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation. FLT3LG cooperates with IL2, IL6, IL7, and IL15 to induce NK cell development and with IL3, IL7 and IL11 to induce terminal B cell maturation. Animal studies also show FLT3LG to reduce the severity of experimentally induced allergic inflammation. FLT3LG is crucial for steady-state pDC and cDC development. A lack of FLT3L results in low levels of DCs.

Source
Recombinant Human Flt-3 Ligand, His Tag (FLL-H5223) is expressed from human 293 cells (HEK293). It contains AA Thr 27 - Pro 185 (Accession # P49771-1).
Predicted N-terminus: Thr 27

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 19.9 kDa. The protein migrates as 28-30 kDa and 31-33 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per 1 μg of the rhFLT3LG by the LAL method.

Purity
>90% as determined by SDS-PAGE. 

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors"
Oba, Kajihara, Yokoi et al
Cancer Res (2021) 81 (24), 6183-6195
(2) "Dendritic cells play no significant role in the laser-induced choroidal neovascularization model"
Droho, Perlman, Lavine
Sci Rep (2021) 11 (1), 17254
(3) "Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression"
Patel, Oba, Kajihara et al
J Immunol (2021) 207 (5), 1298-1309
Showing 1-3 of 1391 papers.